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post-transplant was 69% (95%CI 64%, 74%). For pts with malignant
disease, disease-free survival at 1 year was 50% (95% CI 43%, 56%).
Based on Cox proportional hazards models, the success of transplan-
tation was predominantly dependent on pt characteristics: pts with
non-malign disease, CMV seronegativity, and males had improved
outcomes. CD34 dose was associated with improved neutrophil and
platelet engraftment. In multivariate analyses, TNC (95% pts had
2.5  107/kg), HLA match (4/6 vs 5 or 6/6 types at transplant) or
HR HLA match (8/10 vs 8/10) were not signiﬁcantly associated
with any of the end points. In conclusion, HLA 4-6 of 6 matched
CBUs with 2.5  107/kg TNC provide excellent transplant results
for pediatric patients with malign (OS 57% [95% CI 50%, 63%] at 1
year) and non-malign (OS 71% [95% CI 61%, 80%] at 1 year)
diseases.
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UNRELATED CORD BLOOD TRANSPLANTATION AFTER MYELOABLA-
TIVE CONDITIONING IN ADULT PATIENTS WITH ACUTE LEUKEMIA
Ooi, J., Takahashi, S., Tomonari, A., Asano, S., Tojo, A. Department
of Hematology and Oncology, Institute of Medical Science, University of
Tokyo, Tokyo, Japan.
Although allogeneic stem cell transplantation from a human
leukocyte antigen (HLA)-identical related donor offers a potential
cure for patients with acute leukemia, a suitably matched related
donor is unavailable for approximately two-thirds of patients. Re-
cently, umbilical cord blood from unrelated donors has been used
as an alternative stem cell source for adult patients with hemato-
logical malignancies. Here, we updated the results of unrelated
cord blood transplantation (CBT) after myeloablative conditioning
for 69 adult patients with acute leukemia. Between August 1998
and April 2005, 69 adult patients with acute leukemia were treated
with unrelated CBT at The Institute of Medical Science, Univer-
sity of Tokyo. Diagnoses at transplantation included de novo AML
(n  38), ALL (n  16), and MDS-related secondary AML (n 
15). All patients received four fractionated 12 Gy total body irra-
diation and chemotherapy as myeloablative conditioning. 66 pa-
tients received standard cyclosporine (CyA) and methotrexate, and
3 patients received CyA only as a graft-versus-host disease
(GVHD) prophylaxis. Among the patients the median age was 41
years (range, 18-55 years), the median weight was 55 kg (range,
36-76 kg) and the median number of cryopreserved nucleated cells
was 2.50  107/kg (range, 1.16-5.29  107/kg). 65 patients had
myeloid reconstitution and the median time to more than 0.5 
109/L absolute neutrophil count was 21 days. A self-sustained
platelet count more than 50 109/L was achieved in 59 patients at
a median time of 39 days. Acute GVHD above grade II occurred in
39 of 65 evaluable patients and chronic GVHD occurred in 37 of
47 evaluable patients. Among 37 chronic GVHD patients, 12
patients were extensive type. 46 patients are alive and free of
disease at between 126 and 2562 days after transplantation. With a
median follow-up of 1259 days, the probability of disease-free
survival at 3 years was 69.0%. These results suggest that adult acute
leukemia patients without suitable related or unrelated bone mar-
row donors should be considered as candidates for CBT.
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IMPACT OF DONOR KIR GENOTYPE AND RECIPIENT HLA LIGAND
INCOMPATIBILITY ON RELAPSE RELATED MORTALITY AND ACUTE
GRAFT VERSUS HOST DISEASE IN HIGH-RISK PATIENTS UNDERGOING
HAPLOIDENTICAL NON-MYELOABLATIVE PERIPHERAL BLOOD STEM
CELL TRANSPLANTS: DIFFERENCES BETWEEN LYMPHOID AND MY-
ELOID MALIGNANCIES
Prasad, V.K.1, Chen, D.-F.2, Reinsmoen, N.L.2, Broadwater, G.3,
Chao, N.J.4, Rizzieri, D.A.4 1Pediatric Blood and Marrow Transplan-
tation Program, Duke University Medical Center (DUMC), Durham,
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Pathology, DUMC, Durham, NC; 3Cancer Center Biostatistics,
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Failure to recognize the appropriate HLA class I ligands on the
target cell triggers the inhibitory killer Ig-like receptors (KIR) to
initiate cytotoxicity and may contribute to graft-vs.-leukemia
(GVL) effect. Past studies have shown GVL advantage of the
absence (incompatibility) of recipient HLA ligands to donor KIR
genes in select patients (pts) undergoing myeloablative transplan-
tation. Here we examine if similar advantage is seen in non-
myeloablative transplant (NMT). The KIR-HLA ligand combina-
tions studied were: KIR2DL1-Cw4 (Asn77Lys80); KIR2DL2/3-
Cw3 (Ser77Asn80); KIR3DL1-Bw4; and KIR3DL2-A3/A11. The
KIR typing was performed by rSSOP and HLA-C allele typing by
SBT. Twenty-two lymphoid malignancy (LM) pts with ALL, HD,
or NHL and 20 myeloid malignancy (MM) pts with AML or MDS
were studied. The median age of LM and MM were both 45 years.
All had relapsed/refractory disease, and/or co-morbidities preclud-
ing ablative transplantation. Peripheral blood hematopoietic stem
cell graft from haploidentical family donors with alemtuzumab (20
mg  5), ﬂudarabine (30 mg/m2  4), and cyclophosphamide (500
mg/m2 4) regimen and mycophenolate cyclosporine in vitro
alemtuzumab prophylaxis was used. Most donors were 3-4/6 HLA
matched (75% in MM and 82% in LM). Each pair was evaluated
for the donor KIR genotype and lack of corresponding class I
ligands. Kaplan-Meier curves were compared using log-rank test.
The impact of NK cell cytotoxicity was assessed by relapse related
mortality (RRM). RRM in MM group was appreciably lower if
there was KIR/HLA-C ligand incompatibility (P .059). One year
probability of RRM is 14% (95% conﬁdence: 0-37%) in the in-
compatible group compared to 71% (95% conﬁdence: 28-89%) in
the compatible group (P  .059). In addition, RRM is lower
though not reaching statistical signiﬁcance (P  .070) if the in-
compatibility existed for 2 or 3 KIR/HLA ligand combinations
(17%; 95% conﬁdence: 0-42%) in comparison to no or 1 combi-
nation (66%; 95% conﬁdence: 25-85%). There were no differ-
ences in RRM in LM group (P  .784 for HLA-C; P  .16 for
Bw4; 0.752 for A3/11) with regard to KIR/HLA ligand matching.
KIR-HLA ligand incompatibility did not increase the probability
of grade 2-4 AGVHD in the MM group (P .247 for HLA-C; P
.467 for Bw4; 0.357 for A3/11). These results suggest that KIR/
HLA ligand incompatibility contributes to GVL effect without an




ADOPTIVE IMMUNOTHERAPY WITH ALLODEPLETED DONOR T-CELLS
IMPROVES IMMUNE RECONSTITUTION AFTER HAPLOIDENTICAL STEM
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One of the major barriers to the broader use of haploidentical
stem cell transplantation (SCT) is the high mortality from viral
infections due to poor immune reconstitution. One approach to
safely overcome this problem is to infuse donor T-cells from which
alloreactive lymphocytes have been selectively depleted, but the
immunological beneﬁt of this approach is unknown. We have
previously demonstrated that an anti-CD25 immunotoxin effec-
tively depletes alloreactive donor lymphocytes from co-cultures of
donor mononuclear cells and host lymphoblastoid cell lines with
preservation of in vitro anti-viral responses. In the current study we
have compared immune reconstitution after allodepleted donor
T-cells were infused at 2 dose levels into recipients of haploiden-
tical SCT. Patients were scheduled to receive 3 doses of allode-
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pleted cells and 8 patients were treated at 104 cells/kg/dose and 8
patients received 105 cells/kg/dose. Patients receiving 105 cells/kg/
dose showed signiﬁcantly improved T-cell recovery at 3, 4 and 5
months post-SCT compared with those receiving 104 cells/kg/dose
(P  .05). Accelerated T-cell recovery occurred as a result of
expansion of the effector memory (CD45RACCR-7) population
(P  .05), indicating derivation from the infused allodepleted cells
and that protective T-cell responses are likely to be long-lived.
Using tetramer and ELISPOT assays, we have observed CMV and
EBV-speciﬁc responses in 4/6 evaluable patients at dose level 2 as
early as 2-4 months post-transplant, whereas such responses were
not observed until 6-12 months in dose level 1 patients. The
incidence of signiﬁcant acute (2/16) and chronic GVHD (2/13) was
low. At a median follow-up of 25 months, only 1 patient has died
from infection and 8 of 16 of these high-risk patients are disease-
free. These data demonstrate that allodepleted donor T-cells can
be safely be used to improve T-cell reconstitution after haploiden-
tical SCT and that total cell doses of 3  105/kg are sufﬁcient to
confer useful anti-viral immunity. This approach may broaden the
applicability of haploidentical SCT by reducing infection-associ-
ated mortality (Table 1).
Table 1. Comparison of CD3 ve T-Cell Recovery between Dose
















1 7 0 6 4 .215
2 7 2 6 20 .216
3* 7* 2* 6* 616* .016*
4* 6* 112* 6* 747* .017*
5* 6* 175* 6* 900* .04*
6 5 488 5 1421 .129
9 3 1047 2 1450 .787
*Signiﬁcant increases in T-cell numbers in dose level 2 compared
to dose level 1.
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PERIPHERAL CD4CD25 REGULATORY T CELLS (Treg) BLOCK ALLO-
REACTIVE HOST ANTI-DONOR T CELLS IN CANINE MIXED HEMATO-
POIETIC CHIMERAS
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CD4CD25 Treg cells may be important regulators for the
maintenance of immune tolerance after allogeneic hematopoietic
cell transplantation (HCT). In the canine model of nonmyeloab-
lative HCT, stable mixed hematopoietic chimerism persists follow-
ing 2 gray total body irradiation, dog leukocyte antigen (DLA)-
identical HCT and short-term postgrafting immunosuppression
with mycophenolate mofetil and cyclosporine. We hypothesized
that CD4CD25Treg are an important component of the cellular
mechanism maintaining stable mixed chimerism. We asked if de-
pletion of CD4CD25 Treg from peripheral blood mononuclear
cells (PBMC) from dogs with stable mixed chimerism could gen-
erate minor histocompatibility antigen (mHAg)-speciﬁc, host anti-
donor cytotoxic T lymphocytes (CTL). Responder PBMC from 4
mixed chimeric dogs were cultured in MLC with irradiated,
CD34 derived dendritic cells (DC) from the respective DLA-
identical HCT donor. On day 4 of MLC, CD4CD25 T cells
were depleted by either immunomagnetic selection (Miltenyi) us-
ing the CD25 monoclonal antibody (ACT-1) or the addition of
1011 M denileukin diftitox (DAB389IL-2, Ontak). DAB389IL-2 is
a fusion protein of the ADP-ribosyltransferase domain of diphthe-
ria toxin and IL-2. Depletion of CD4CD25bright was 60%-66%
with immunomagnetic selection and 70%-77% with DAB389IL-2.
A secondary MLC was established with CD4CD25 depleted
responder cells and DC from the respective DLA-identical HCT
donor. There was a 54%-95% increase in proliferation of cells
depleted of CD4CD25 T cells with immunomagnetic selection
and a 121%-133% increase in proliferation of DAB389IL-2 treated
cells compared with non-depleted responder cells. We evaluated
mHAg-speciﬁc CTL activity of the CD4CD25 depleted re-
sponder T cells by 51Cr release assay. There was 74%-82% speciﬁc
lysis of the respective HCT donor cells by the CD4CD25
depleted responder T cells, while the non-depleted control re-
sponder cells had 4%-6% speciﬁc lysis. PCR analysis with infor-
mative microsatellite markers conﬁrmed the alloreactive CTL
were of host origin. Depletion of CD4CD25 Treg from PBMC
of mixed chimeras permitted the emergence of host anti-donor
mHAg-speciﬁc CTL. The data suggest (1) mHAg-speciﬁc host
anti-donor T cells persist in stable mixed chimeric dogs, (2) pe-
ripheral CD4CD25 Treg prevent alloreactive immune re-
sponses, (3) mixed hematopoietic chimerism established without T
cell depletion relies on peripheral immune tolerance mechanisms.
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PR1 VACCINE AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION
Qazilbash, M.H., Rios, R., Thall, P.F., Wang, X., Wieder, E., Lu, S.,
Kant, S., Giralt, S.A., Estey, E.H., Cortes, J., Champlin, R.E.,
Komanduri, K., Molldrem, J.J. University of Texas M.D. Anderson
Cancer Center, Houston, TX.
Background: PR1 peptide has been established as a humanmyeloid
leukemia-associated antigen. We studied PR1 peptide vaccine in a
phase I/II clinical trial in HLA-A2 patients with AML, MDS and
CML. There were concerns that prior hematopoietic stem cell trans-
plantation (HSCT)might inhibit an immune response to PR1 vaccine
due to impaired immune reconstitution. To address this question we
studied the outcome in 19 patients who received PR1 vaccine after a
HSCT. Methods: Nineteen patients (AML/MDS 13 and CML 6)
were vaccinated a median of 10 months after one of the following
HSCT: allogeneic related 12, allogeneic unrelated 3, autologous 3,
and syngeneic 1. At the time of vaccination, 7 patients were in CR, 5
had relapsed or refractory CML and 7 had relapsed or refractory
AML. Patients were off systemic immunosuppressive therapy for at
least 2 weeks, and without active acute or chronic GVHD. The
vaccine was given subcutaneously every 3 weeks for a total of 3
injections at one of three dose levels: 0.25, 0.5 and 1.0 mg. Immune
response to the vaccine (IRV) was deﬁned as a doubling of PR1-
speciﬁc cytotoxic T lymphocytes by PR1/HLA-A2 tetramer assay.
Results: After a median follow-up of 23 months, toxicity was limited
to grade I/II injection site reactions, with no exacerbations of acute or
chronic GVHD. PR1-vaccine induced immune responses were ob-
served in 9/18 (50%) evaluable patients. Of the 9 patients with PR1-
speciﬁc immune response, 6 remained in continuous complete remis-
sion (CCR), 2 patients with measurable disease achieved a complete
remission and 1 patient had hematologic improvement. Of the 9
patients without an immune response, 6 had no clinical response/
disease progression, 2 remained in CCR and 1 had hematologic
improvement. There was a signiﬁcant association between the devel-
opment of PR1-speciﬁc immune response and a clinical response (P
.03). Median progression-free survival (PFS) in IRV vs. IRV
patients was 23.4 months vs. 4.1 months, respectively (P  .36). On
univariate and multivariate Cox proportional hazards analysis, mini-
mal residual disease (P  .009) was associated with a lower risk of
progression. Conclusions: PR1 vaccine can produce a PR1-speciﬁc
immune response in patients after HSCT. This immune response is
associated with a better clinical response and a trend towards longer
progression-free survival.
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ACTIVATION OF LMP1- AND LMP2-SPECIFIC T-CELLS FOR THE IMMU-
NOTHERAPY OF EBV POSITIVE MALIGNANCIES WITH AN ADENOVIRAL
VECTOR ENCODING FULL LENGTH LMP1 AND LMP2
Ratnayake, M., Louis, C., Leen, A., Rooney, C.M., Brenner, M.K.,
Heslop, H.E., Gottschalk, S. Center for Cell and Gene Therapy at Baylor
College of Medicine, Houston, TX.
Background: LMP1 and LMP2 are potential targets for the
immunotherapy of EBV-positive malignancies such as nasopharyn-
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